Company intelligence / Profile preview

SurgeCare

San Francisco, California, United Stateslife-sciences-europe.com ↗

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

SurgeCare has developed a proprietary AI-driven immune fingerprinting technology that predicts the risk of postoperative complications. Clinical studies from 2022–2023 showed their prototype outperformed existing methods by more than three times in predictive capability. The PreCyte® product is entering its final industrialization phase with pilot deployment planned for late 2024.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceDiagnostic platform
Industry: Protein Biomarker Diagnostics

Partnerships

Not explicitly listed; collaborating with research institutions and hospitals on clinical validation and pilot deployments[5]

Beyond the preview

Go deeper on SurgeCare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SurgeCare.

Explore the full profile